Stephen Beatty1, Usha Chakravarthy2, John M Nolan1, Katherine A Muldrew3, Jayne V Woodside3, Frances Denny4, Michael R Stevenson3. 1. Macular Pigment Research Group, Waterford Institute of Technology, Waterford City, Waterford, Republic of Ireland. 2. Center for Vascular and Vision Sciences, Institute of Clinical Science, The Royal Victoria Hospital, Belfast, Northern Ireland. Electronic address: u.chakravarthy@qub.ac.uk. 3. Centre for Public Health, Queen's University of Belfast, Northern Ireland. 4. Exploristics, Forsyth House, Cromac Square Belfast, Northern Ireland.
Abstract
PURPOSE: To report the secondary outcomes in the Carotenoids with Coantioxidants in Age-Related Maculopathy trial. DESIGN: Randomized double-masked placebo-controlled clinical trial (registered as ISRCTN 94557601). PARTICIPANTS: Participants included 433 adults 55 years of age or older with early age-related macular degeneration (AMD) in 1 eye and late-stage disease in the fellow eye (group 1) or early AMD in both eyes (group 2). INTERVENTION: An oral preparation containing lutein (L), zeaxanthin (Z), vitamin C, vitamin E, copper, and zinc or placebo. Best-corrected visual acuity (BCVA), contrast sensitivity (CS), Raman spectroscopy, stereoscopic colour fundus photography, and serum sampling were performed every 6 months with a minimum follow-up time of 12 months. MAIN OUTCOME MEASURES: Secondary outcomes included differences in BCVA (at 24 and 36 months), CS, Raman counts, serum antioxidant levels, and progression along the AMD severity scale (at 12, 24, and 36 months). RESULTS: The differential between active and placebo groups increased steadily, with average BCVA in the former being approximately 4.8 letters better than the latter for those who had 36 months of follow-up, and this difference was statistically significant (P = 0.04). In the longitudinal analysis, for a 1-log-unit increase in serum L, visual acuity was better by 1.4 letters (95% confidence interval, 0.3-2.5; P = 0.01), and a slower progression along a morphologic severity scale (P = 0.014) was observed. CONCLUSIONS:Functional and morphologic benefits were observed in key secondary outcomes after supplementation with L, Z, and coantioxidants in persons with early AMD.
RCT Entities:
PURPOSE: To report the secondary outcomes in the Carotenoids with Coantioxidants in Age-Related Maculopathy trial. DESIGN: Randomized double-masked placebo-controlled clinical trial (registered as ISRCTN 94557601). PARTICIPANTS: Participants included 433 adults 55 years of age or older with early age-related macular degeneration (AMD) in 1 eye and late-stage disease in the fellow eye (group 1) or early AMD in both eyes (group 2). INTERVENTION: An oral preparation containing lutein (L), zeaxanthin (Z), vitamin C, vitamin E, copper, and zinc or placebo. Best-corrected visual acuity (BCVA), contrast sensitivity (CS), Raman spectroscopy, stereoscopic colour fundus photography, and serum sampling were performed every 6 months with a minimum follow-up time of 12 months. MAIN OUTCOME MEASURES: Secondary outcomes included differences in BCVA (at 24 and 36 months), CS, Raman counts, serum antioxidant levels, and progression along the AMD severity scale (at 12, 24, and 36 months). RESULTS: The differential between active and placebo groups increased steadily, with average BCVA in the former being approximately 4.8 letters better than the latter for those who had 36 months of follow-up, and this difference was statistically significant (P = 0.04). In the longitudinal analysis, for a 1-log-unit increase in serum L, visual acuity was better by 1.4 letters (95% confidence interval, 0.3-2.5; P = 0.01), and a slower progression along a morphologic severity scale (P = 0.014) was observed. CONCLUSIONS: Functional and morphologic benefits were observed in key secondary outcomes after supplementation with L, Z, and coantioxidants in persons with early AMD.
Authors: Magdalena M Olchawa; Anja M Herrnreiter; Anna K Pilat; Christine M B Skumatz; Magdalena Niziolek-Kierecka; Janice M Burke; Tadeusz J Sarna Journal: Free Radic Biol Med Date: 2015-10-23 Impact factor: 7.376
Authors: Bradley S Henriksen; Gary Chan; Robert O Hoffman; Mohsen Sharifzadeh; Igor V Ermakov; Werner Gellermann; Paul S Bernstein Journal: Invest Ophthalmol Vis Sci Date: 2013-08-15 Impact factor: 4.799
Authors: Clare Kirwan; John M Nolan; Jim Stack; Tara C B Moore; Stephen Beatty Journal: Graefes Arch Clin Exp Ophthalmol Date: 2015-05-13 Impact factor: 3.117
Authors: William G Christen; Robert J Glynn; Joann E Manson; Jean MacFadyen; Vadim Bubes; Miriam Schvartz; Julie E Buring; Howard D Sesso; J Michael Gaziano Journal: Ophthalmology Date: 2013-11-20 Impact factor: 12.079
Authors: Paul S Bernstein; Binxing Li; Preejith P Vachali; Aruna Gorusupudi; Rajalekshmy Shyam; Bradley S Henriksen; John M Nolan Journal: Prog Retin Eye Res Date: 2015-11-02 Impact factor: 21.198